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Abstract
Background: Guidelines regarding treatment for autoimmune hepatitis (AIH) favour 
two strategies for azathioprine (AZA) introduction: concurrent with steroids at induc-
tion or delayed by 2-4 weeks. The safety and efficacy of both strategies have been 
unexplored.
Methods: We established a cohort of 900 AIH patients from 12 centres in 7 European 
countries. There were 631 patients who used AZA as part of the therapeutic regi-
men. We distinguished two groups: patients with early AZA (<2 weeks) or delayed 
AZA initiation (≥2 weeks). Primary outcome was discontinuation of AZA in the first 
year of treatment. Cox regression and propensity score matching was performed to 
determine difference in outcomes between groups.
Results: Patients with early AZA initiation had significantly lower transaminases and 
bilirubin at baseline. Discontinuation rates of AZA did not differ between early and 
delayed starters (16.6% vs 14.2%), which did not reach statistical significance (haz-
ard ratio 0.97, 95% confidence interval 0.61-1.55, P = .90). Stratification according 
to baseline disease activity or propensity score matching did not alter the results. 
Main reason for AZA discontinuation was intolerance to treatment (14.0% vs 13.2%, 
P = .78) with nausea and vomiting as main side effects. AIH remission rates were 
comparable among groups.
Conclusion: The discontinuation rate of AZA in AIH treatment is ~15% in the first 
year of treatment. Early or delayed AZA initiation does not differ in remission and 
discontinuation rates in AIH induction therapy. Our data suggest that either strategy 
may be used as part of AIH treatment.
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1  | INTRODUC TION
Cornerstone of autoimmune hepatitis (AIH) treatment is steroid 
induction therapy, consisting of predniso(lo)ne, and subsequent 
addition of azathioprine (AZA).1 The use of AZA as therapy for 
AIH was first described anecdotally in the 1960s,2 and controlled 
studies over the next decades heralded the use of AZA as first-line 
maintenance therapy in AIH.3-5 One study with a long follow-up 
found that AIH patients are able to withdraw from steroids when 
on AZA therapy, while maintaining remission.6 Therefore, mainte-
nance therapy with AZA is considered the mainstay treatment for 
AIH. While the vast majority of patients tolerate AZA therapy, ap-
proximately 10%-20% of patients may develop side effects rang-
ing from mild nausea to severe cytopenia or cholestatic hepatitis, 
which may lead to discontinuation of the drug. The exact incidence 
of AZA-related side effects in AIH remains largely unknown since 
current evidence is based on trials that were conducted decades 
ago.7
There is ambiguity when to initiate AZA therapy after AIH 
onset. The American Association of Study of Liver Diseases 
(AASLD) guideline suggests to start AZA simultaneously with 
predniso(lo)ne,8 whereas the European Association for Study of 
the Liver (EASL) clinical practice guideline suggests that introduc-
tion of AZA could be delayed by 2 or more weeks. This would help 
to resolve possible diagnostic uncertainties and to discriminate 
between AZA-induced hepatotoxicity and primary non-response.9 
Formal evidence that supports either strategy is absent from 
the literature. Using data from a large multicenter international 
retrospective cohort, we aimed to investigate the role of early 
(<2 weeks) vs delayed (≥2 weeks) introduction of AZA therapy 
and its effect on discontinuation rates, side effects of therapy and 
efficacy.
2  | METHODS
2.1 | Study design
We performed a retrospective cohort study with AIH patients from 
12 centres in 7 countries in Europe. Patients were included if they 
were ≥18 years old and had a ‘probable’ or ‘definite’ AIH diagnosis 
according to the simplified diagnostic criteria established by the 
International Autoimmune Hepatitis Group.10 Only patients who 
used AZA as first-line treatment and who started AZA within the 
first 26 weeks after diagnosis were included in this study. Patients 
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Key points
• Discontinuation rate and efficacy of therapy for AIH 
in the first year of treatment is independent of time of 
AZA initiation.
• AZA discontinuation occurs in 15% of AIH patients in 
the first year.
• Discontinuation rates do not differ between patients 
who start AZA concurrent to steroid treatment and 
those who start AZA ≥2 weeks later.
• Most common side effects of AZA therapy in AIH are 
nausea, emesis en diarrhoea.
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with signs of variant syndromes with primary biliary cholangitis or 
primary sclerosing cholangitis were excluded. Patients with other 
forms of liver disease, such as histologically proven non-alcoholic 
steatohepatitis or viral hepatitis, were excluded as well. Ethics ap-
proval was waived after review by local institutional review board.
2.2 | Data collection
We collected patient data from original patient records and local da-
tabases. Demographical, serological, histological, biochemical and 
treatment data were collected using a predefined electronic case 
report form and stored in an online database (Castor Electronic Data 
Capture, CIWIT BV, Amsterdam, The Netherlands). In patients who 
had stopped AZA therapy, additional data were collected regarding 
reason of cessation of AZA therapy, duration of AZA use and switch 
to second-line therapy.
2.3 | Outcomes
Primary outcome was percentage of patients who discontinued AZA 
within the first year of treatment. Patients who had discontinued 
AZA therapy were classified as: (a) stopped as a result of intolerance 
to treatment or (b) stopped because of an insufficient response to 
treatment, as assessed by the treating physician. These two outcome 
measures were also analysed as separate endpoints. Adverse events 
that led to discontinuation of AZA therapy were collected from the 
patient record and included nausea, emesis, diarrhoea, rash, cyto-
penia, infection, pancreatitis, hepatitis, fever, arthralgia/myalgia and 
skin abnormalities. Secondary outcomes were serum transaminases 
below the upper limit of normal (ULN) after 26 weeks and 52 weeks 
of treatment. Both alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) needed to be below the ULN in order to 
meet this endpoint. In case an ALT or AST value was missing, the 
known ALT or AST value had to be below the ULN in order to meet 
this outcome. We used the gender-specific ULN of each centre for 
ALT and AST. In addition, biochemical remission was a secondary 
outcome in the subgroup of patients with measured immunoglobulin 
G (IgG), which was defined a normalization of serum transaminases 
and IgG.
2.4 | Analysis
Based on the initial start date of AZA, patients were divided into 
two groups: patients who had received AZA therapy within 2 weeks 
of initiation of steroid therapy (‘early’ AZA therapy) and patients 
who had received AZA 2-24 weeks after steroid treatment (‘de-
layed’ AZA therapy). The choice between either therapeutic strate-
gies was left at the discretion of the attending physician. Univariate 
comparisons between the groups were made using the chi-square, 
Mann-Whitney U or t test as appropriate. We used multivariable 
Cox regression, with the early AZA starters as group of interest, to 
determine differences in primary outcome between the two groups 
and to correct for possible confounders with time until AZA discon-
tinuation as time-dependent variable. We predefined a number of 
possible confounders that could have an association with the pri-
mary outcome. These included age, institute, gender and presence 
of cirrhosis. Significant baseline differences between the two groups 
were also added to the multivariable regression model. Results of 
the Cox regression are presented as hazard ratio's (HR) with 95% 
confidence intervals (CI) with the early AZA starts as group of in-
terest. We performed multivariable logistic regression for the end-
points of normalization of transaminases and biochemical remission 
at weeks 26 and 52. Results of the logistic regression are presented 
as odds ratio's (OR) with 95% CI's. In addition, we used propensity 
score matching to compare matched groups of patients based on 
baseline disease activity. We used baseline values of transaminases 
and bilirubin to calculate a propensity score with early or delayed 
AZA initiation as dependent variable. Cases were matched 1:1 using 
nearest-neighbour matching. Additionally, we performed a subgroup 
analysis in all patients, stratified according to baseline disease ac-
tivity, based on AST level. Patients were divided into three equal 
groups based on their baseline AST, in order to detect differences 
in our primary outcome. A P-value < .05 was considered statistically 
significant. Analyses were conducted with SPSS version 25 (IBM 
Corporation, Armonk, NY, USA).
3  | RESULTS
3.1 | Population
Our original cohort consisted of 900 AIH patients. Some 244 pa-
tients were excluded because either they did not use AZA as part 
of maintenance therapy or because of missing data. Another 25 
patients were excluded because AZA was started >26 weeks after 
start of steroid induction therapy. Our final cohort consisted of 631 
patients. A total of 229 patients (36.3%) started AZA concurrent 
with steroid induction therapy, while 402 patients (63.7%) started 
AZA only 1-24 weeks after induction. Most patients (74.5%) were 
woman and mean age at diagnosis was 48.7 years old (standard 
deviation 16.6 years). Patients with early AZA initiation had lower 
biochemical disease activity at baseline: median ALT (5.13 × ULN 
vs 14.51 × ULN, P < .001), AST (3.73 × ULN vs 14.26 × ULN, 
P < .001) and bilirubin (22.0 vs 50.5 µmol/L, P < .001) were all 
lower when compared to patients with a delayed introduction of 
AZA (Table 1). Median IgG (data available for 541 cases) was also 
significantly lower in patients with early AZA therapy (18.0 vs 
21.8 g/L, P < .001). The presence of cirrhosis at index biopsy was 
equally distributed between both groups (19.2% vs 16.7%, P = .42), 
while acute-severe AIH (AS-AIH, defined as absence of cirrhosis 
and an INR > 1.511) occurred more frequently in the group with 
delayed AZA introduction (5.7% vs 13.9%, P < .001). Patients with 
early AZA were given lower initial predniso(lo)ne dosages (0.58 vs 
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0.62 mg/kg/day, P = .02) and higher initial AZA dosages (0.86 mg/
kg/day vs 0.80 mg/kg/day, P = .02).
3.2 | Discontinuation of AZA
Ninety-five (15.1%) patients in the entire cohort discontinued AZA 
therapy in the first year of treatment. Discontinuation rates did not 
differ between early (<2 weeks) and delayed (≥2 weeks) AZA initia-
tion (16.6% vs 14.2%, P = .42). Multivariable Cox regression with 
correction for institute, age, gender, cirrhosis, AST at baseline, ini-
tial predniso(lo)ne dose and initial AZA dose showed that there was 
no significant difference between groups of AZA discontinuation 
rates (corrected HR 0.97, 95% CI 0.61-1.55, P = .90) (Table 2). In both 
groups most patients discontinued AZA due to intolerance to treat-
ment (14.0% vs 13.2%, P = .78) (Table 3), which was not statistically 
significant after multivariable logistic regression (OR 0.41, 95% CI 
0.08-2.08, P = .41). Discontinuation rates as a result of insufficient 
response were similar among both groups (univariate analysis 2.6% 
vs 1.0%, P = .12, multivariate analysis OR 2.44, 95% CI 0.48-12.39, 
P = .28).
Most frequent reasons for stopping AZA resulted from gastroin-
testinal toxicity such as nausea (6.6% vs 7.0%, P = .84), emesis (3.1% 
vs 3.2%, P = .90) and hepatitis (2.2% vs 2.5%, P = .81) (Figure 1). 
Patients with gastrointestinal complaints did not receive higher ini-
tial AZA dosages than patients without gastrointestinal complaints 
(0.74 mg/kg vs 0.74 mg/kg, P = .87).
Three patients (1.3%) in the early AZA initiation group developed 
pancreatitis, while this did not occur in patients from the delayed 
AZA group (P = .02). Pancreatitis developed quickly after AZA initia-
tion (median duration 2 weeks), while cytopenia only developed after 
a median duration of 32 weeks. Hepatitis related to AZA therapy 
developed after a median duration of 6 weeks (Figure S1; Table S1).
Our cohort consisted of 69 patients with AS-AIH, of which the 
majority of patients (81.2%) belonged to the delayed AZA initiation 
group. Overall, AZA discontinuation rates in AS-AIH were lower 
than in patients with ‘normal’ AIH (8.7%). Consequently, rates did 
not differ between early (1/13, 7.7%) and late (5/56, 8.9%) AZA ini-
tiation (P = .89).
3.3 | Discontinuation rates after propensity 
score matching
Using propensity score matching, we established two matched 
groups of 146 patients in the early and delayed AZA initiation group. 
There were no significant baseline differences between the two 
groups. Consequently with our primary analysis, discontinuation 
rates of AZA therapy did not differ between early and delayed AZA 
TA B L E  1   Baseline and treatment characteristics of patients who 
started AZA therapy concurrent with steroid treatment vs patients 
with a delayed introduction of AZA
Early AZA 
initiation
n = 229
Delayed AZA 
initiation
n = 402
P-
value
Female gender, n (%) 163 (71.2%) 307 (76.4%) .15
Age at diagnosis, y (SD) 50.00 (16.51) 47.87 (16.58) .12
Probable AIH, n (%) 100 (43.7%) 157 (39.1%) .26
Definite AIH, n (%) 129 (56.3%) 245 (60.9%) .26
ALT × ULN, median 
(IQR)
5.13 (14.51) 14.51 (24.43) <.001
AST × ULN, median (IQR) 3.73 (15.24) 14.26 (24.39) <.001
Bilirubin (µmol/L), 
median (IQR)
22.0 (56.0) 50.5 (155.8) <.001
IgG (g/L), median (IQR)a  18.0 (9.3) 21.8 (12.1) <.001
Cirrhosis, n (%) 44 (19.2%) 67 (16.7%) .42
AS-AIH, n (%) 13 (5.7%) 56 (13.9%) .001
Median initial 
predniso(lo)ne dose, 
mg (IQR)
40 (35) 40 (30) .02
Median initial 
predniso(lo)ne dose, 
mg/kg (IQR)
0.58 (0.57) 0.62 (0.47) .02
Median initial AZA 
dose, mg (IQR)
50 (50) 50 (25) .004
Median initial AZA 
dose, mg/kg (IQR)
0.86 (0.62) 0.80 (0.38) .02
Abbreviations: AIH, autoimmune hepatitis; ALT, alanine 
aminotransferase; AS-AIH, acute-severe AIH; AST, aspartate 
aminotransferase; AZA, azathioprine; IgG, immunoglobulin G; IQR, 
interquartile range; SD, standard deviation; ULN, upper limit of normal.
aData available for 541 patients. 
TA B L E  2   Results after multivariable Cox and logistic regression for patients with early initiation of AZA therapy
Cox regression Uncorrected HR P-value Corrected HR P-value
Discontinuation of AZA < 52 wk 1.09 (0.72-1.64) .69 0.97 (0.61-1.55)a  .90
Logistic regression Uncorrected OR P-value Corrected OR P-value
Normal transaminases at week 24 0.85 (0.61-1.19) .34 0.74 (0.51-1.06)a  .10
Biochemical remission at week 24 0.88 (0.59-1.31) .53 0.85 (0.55-1.32)a  .47
Normal transaminases at week 52 0.93 (0.63-1.36) .69 0.75 (0.49-1.15)a  .19
Biochemical remission at week 52 1.01 (0.64-1.60) .96 0.96 (0.57-1.62)a  .87
Abbreviations: AZA, azathioprine; HR, hazard ratio; OR, odds ratio.
aIn all multivariable models we adjusted for institute, age, gender, cirrhosis, aspartate aminotransferase at baseline, predniso(lo)ne dose and AZA dose. 
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initiation (16.4% vs 15.8%, P = .87) (Table 4). Additionally, there were 
no differences in rates of normalization of transaminases at week 24 
and week 52 of treatment.
3.4 | Treatment outcomes and switch to second-
line therapy
There were no differences regarding treatment outcomes between 
both study groups. Normalization of transaminases after 26 weeks 
of treatment was achieved by 56.3% of patients from the early AZA 
group compared to 60.2% of patients from the delayed AZA group 
(P = .34) (Table 2). After 52 weeks of treatment, rates of normali-
zation of transaminases were similarly distributed (66.5% vs 68.2%, 
P = .69). When corrected for institute, age, gender, cirrhosis, AST 
at baseline, predniso(lo)ne dose and AZA dose, the OR for nor-
malization of transaminases in early AZA starters was 0.74 (95% CI 
0.51-1.06, P = .10) after 24 weeks of treatment and 0.75 (0.49-1.15, 
P = .19) after 52 weeks of treatment. In a subgroup of patients with 
available IgG data (n = 426 for week 26, n = 367 for week 52), rates 
of biochemical remission were not different between the two groups 
(week 26: 57.5% vs 54.2%, P = .53; week 52: 66.4% vs 66.7%, P = .96). 
Corrected ORs for biochemical remission in patients with early AZA 
initiation were 0.85 (95% CI 0.55-1.32, P = .47) for 24 weeks and 0.96 
(95% CI 0.57-1.62, P = .87) for 52 weeks. Most patients switched to 
second-line therapy shortly after AZA was stopped: 81.6% of pa-
tients in the early AZA group vs 77.2% of patients in the delayed 
group (P = .33). Drugs patients most frequently switched to were 
6-mercaptopurine and mycophenolate mofetil (Table 2).
3.5 | Stratification according to baseline 
disease activity
When stratified according to baseline disease activity, we did not 
find any significant differences for discontinuation rates of AZA 
between the three groups (Table 5). Additionally, occurrence of 
TA B L E  3   Outcomes of patients who started AZA therapy 
concurrent with steroid treatment vs patients with a delayed 
introduction of AZA
Early AZA 
initiation
n = 229
Delayed AZA 
initiation
n = 402
P-
value
Discontinued 
AZA < 52 wk, n (%)
38 (16.6%) 57 (14.2%) .42
Intolerance 32 (14.0%) 53 (13.2%) .78
Nausea 15 (6.6%) 28 (7.0%) .84
Emesis 7 (3.1%) 13 (3.2%) .90
Diarrhoea 2 (0.5%) 2 (0.9%) .57
Rash 1 (0.2%) 1 (0.4%) .69
Cytopenia 3 (1.3%) 8 (2.0%) .53
Infection 0 1 (0.2%) .45
Pancreatitis 3 (1.3%) 0 .02
Hepatitis 5 (2.2%) 10 (2.5%) .81
Fever 0 2 (0.5%) .29
Arthralgia/Myalgia 0 4 (1.0%) .13
Skin abnormalities 0 1 (0.2%) .45
Othera  0 7 (1.7%) .045
Insufficient response 6 (2.6%) 4 (1.0%) .12
Median duration of 
AZA use, wk (IQR)
6.0 (16.25) 6.0 (10.0) .70
Switched to second-
line therapy < 52 wk, 
n (%)
31 (13.5%) 44 (10.9%) .33
MMF 14 (6.1%) 13 (3.2%) .09
6-MP 12 (5.2%) 22 (5.5%) .90
6-TG 0 5 (1.2%) .09
TAC 1 (0.4%) 1 (0.2%) .69
CsA 4 (1.7%) 3 (0.7%) .25
Normalization of 
transaminases at week 
26, n (%)
129 (56.3%) 242 (60.2%) .34
Biochemical remission at 
week 26, n (%)b 
155 (57.5%) 83 (54.2%) .53
Normalization of 
transaminases at week 
52, n (%)c 
121 (66.5%) 242 (68.2%) .69
Biochemical remission at 
week 52, n (%)d 
160 (66.4%) 84 (66.7%) .96
Abbreviations: 6-MP, 6-mercaptopurine; 6-TG, 6-tioguanine; AZA, 
azathioprine; CsA, cyclosporine, IQR, interquartile range; MMF, 
mycophenolate mofetil; TAC, tacrolimus.
aHair loss, dizziness and headache. 
bData available for 423 patients. 
cData available for 537 patients. 
dData available for 367 patients. 
F I G U R E  1   Rates of insufficient response and main side 
effects when patients experienced intolerance which lead to AZA 
discontinuation. AZA, azathioprine. GI, gastrointestinal
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AZA-induced hepatotoxicity, rates of normalization of transami-
nases and biochemical remission at week 52 were not statistically 
different between the three groups.
4  | DISCUSSION
Our study shows that discontinuation rate and efficacy of medi-
cal therapy for AIH in the first year of treatment is independent 
of time of AZA initiation. AZA discontinuation occurred in ~15% 
of our cohort. The exact number of AZA discontinuation rates in 
AIH is unknown and guidelines usually refer to the first trials in-
vestigating AZA in AIH, which lack comparison to real-world prac-
tice.7,8 Real-world data on AZA discontinuation in AIH are limited: 
one study found a discontinuation rate of 6.8%, which is lower than 
the number we report in this study.12 Interestingly, we found that 
discontinuation rates in patients with AS-AIH are lower than in 
patients with non-severe AIH. The reason for this is unknown but 
probably relates to patient- and physician-related factors. We hy-
pothesize that if patients present with severe AIH, physicians will 
apply a more stringent approach towards treatment optimization 
and clinical follow-up, resulting in better treatment outcomes.
Discontinuation rates did not differ between patients who 
started AZA concurrent to steroid treatment and those who started 
AZA ≥2 weeks later. Additionally, we found no differences in rates of 
normalization of transaminases and biochemical remission between 
patients with early or delayed AZA initiation. The strategy of delay-
ing introduction of AZA therapy in order to avoid hepatoxicity in 
the early stages of the disease has found its way to guidelines, but 
evidence supporting this strategy is absent.9,13
Data regarding the specific AZA-related side effects in AIH also 
originate from the first AIH trials or are derived from other auto-in-
flammatory diseases such as ulcerative colitis or rheumatoid ar-
thritis.14,15 One single centre study found that 5% of AIH patients 
discontinued AZA therapy as a result of side effects within 1 month 
of AZA initiation, compared to 29% of patients with Crohn's dis-
ease.16 We report similar rates and found that 13.4% of patients dis-
continued AZA owing to side effects, and 5.7% did so within the first 
TA B L E  4   Baseline characteristics and primary outcome after 
propensity score matching. A propensity score was created based 
on baseline disease activity. The matched cohort consisted of 292 
patients
Early AZA 
initiation
n = 146
Delayed AZA 
initiation
n = 146
P-
value
Baseline characteristics
Female gender, n (%) 102 (69.9%) 114 (78.1%) .11
Age at diagnosis, y 
(SD)
50.70 (16.67) 47.37 (16.18) .08
ALT × ULN, median 
(IQR)
7.26 (17.32) 8.38 (14.33) .49
AST × ULN, median 
(IQR)
6.94 (15.65) 6.80 (15.59) .90
Bilirubin (µmol/L), 
median (IQR)
26.8 (66.3) 34.0 (102.0) .24
IgG (g/L), median 
(IQR)a 
19.31 (11.4) 20.74 (12.9) .08
Cirrhosis, n (%) 30 (20.5%) 33 (22.6%) .67
AS-AIH, n (%) 8 (5.5%) 11 (7.5%) .48
Median initial 
predniso(lo)ne dose, 
mg/kg (IQR)
0.60 (0.55) 0.57 (0.43) .99
Median initial AZA 
dose, mg (IQR)
50 (50) 50 (25) .17
Median initial AZA 
dose, mg/kg (IQR)
0.82 (0.49) 0.77 (0.36) .35
Outcomes
Discontinued 
AZA < 52 wk, n (%)
24 (16.4%) 23 (15.8%) .87
Normal transaminases 
at week 24, n (%)
76 (52.1%) 84 (57.5%) .35
Normal transaminases 
at week 52, n (%)a 
78 (67.2%) 83 (64.3%) .63
Abbreviations: ALT, alanine aminotransferase; AS-AIH, acute-severe 
autoimmune hepatitis; AST, aspartate aminotransferase; AZA, 
azathioprine; IgG, immunoglobulin G; IQR, interquartile range; SD, 
standard deviation; ULN, upper limit of normal.
aData available for 245 patients. 
TA B L E  5   Rates of AZA discontinuation < 52 wk stratified 
according to baseline AST levels
Early AZA 
initiation
Delayed AZA 
initiation
P-
value
AST baseline 0.03-4.8 × ULN
Discontinued 
AZA < 52 wk, n (%)
24 (19.5%) 20 (23.0%) .54
Normal TA week 52 58 (63.7%) 47 (63.5%) .98
Biochemical remission 
week 52
N = 116
39 (60.0%) 30 (58.8%) .90
Hepatotoxicity 2 (1.6%) 2 (2.3%) .73
AST baseline 4.9-19.4 × ULN
Discontinued 
AZA < 52 wk, n (%)
9 (15.5%) 22 (14.9%) .91
Normal TA week 52 28 (60.9%) 89 (66.9%) .46
Biochemical remission 
week 52
N = 128
22 (71.0%) 60 (61.9%) .36
Hepatotoxicity 1 (1.7%) 6 (4.1%) .41
AST baseline 19.5-136 × ULN at baseline
Discontinued 
AZA < 52 wk, n (%)
5 (11.1%) 15 (9.0%) .67
Normal TA week 52 34 (79.1%) 106 (72.1%) .36
Biochemical remission 
week 52
N = 121
23 (82.1%) 70 (75.3%) .45
Hepatotoxicity 2 (4.4%) 2 (1.2%) .16
Abbreviations: AST, aspartate aminotransferase; AZA, azathioprine; TA, 
transaminases; ULN, upper limit of normal.
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month. We found that acute pancreatitis related to AZA therapy is 
more likely to occur in the first weeks after initiation, while cytope-
nia may occur up to 40 weeks after initiation of treatment. These 
findings provide a better understanding of the temporal dynamics 
between type of and duration of AZA-related adverse events. We 
observed that the gastrointestinal toxicity such as nausea, emesis 
and diarrhoea occurs most frequently in this population. We did not 
find a relationship between AZA dose and occurrence of gastroin-
testinal complaints, suggesting that gastrointestinal toxicity caused 
by AZA use is an idiosyncratic reaction.
Our study shows that patients with a delayed AZA introduction 
are more likely to have high transaminases at baseline, which sug-
gests that some physicians had been reluctant to start AZA in these 
patients. However, when stratified according to baseline disease ac-
tivity, we found that there were no differences in discontinuation 
rates between early or delayed starters of AZA, indicating that tim-
ing of introduction did not exert a profound effect on this parameter. 
Furthermore, there were no differences regarding normalization of 
transaminases and biochemical remission between early or delayed 
introduction of AZA, suggesting that delayed introduction does not 
impair treatment efficacy. We observed a statically significant dif-
ference in initial AZA dose between the early and delayed groups. 
Patients with early AZA initiation were treated with slightly higher 
AZA dosages than patients with delayed AZA initiation, suggesting 
that higher AZA dosages could have influenced our results. However, 
we argue that the difference of 0.06 mg/kg (translating to ~4 mg 
AZA in a 70 kg patient) is of little clinical relevance. Furthermore, we 
corrected for AZA dose in our multivariate analyses.
Our study has some inherent limitations. First, because of the 
retrospective design of our study, there is a risk of selection bias and 
confounding by indication. Only patients with sufficient data were 
included in this study, limiting the generalizability. This is, however, 
the largest multicenter study to provide a real-world insight in rea-
sons for stopping AZA therapy in AIH treatment. Second, we used 
assessment from the treating physician to define AZA-related side 
effects, instead of a priori standardized definitions, which would be 
difficult to assess owing to possible under-reporting in patients' re-
cords. We chose discontinuation of AZA as our primary endpoint 
because, in case of AZA intolerance or insufficient response, stop-
ping of AZA will be the likely consequence. Third, we do not provide 
any data on use of 6-thioguanine nucleotide levels (6-TGN) for treat-
ment monitoring in AIH. Although there may be a clinical benefit 
in therapeutic drug monitoring of AIH patients while on thiopurine 
therapy,17-19 we found that the practice of measuring 6-TGN levels 
was not broadly established. Fourth, we do not provide data on the 
long-term risk of AZA use. It is known that long-term use of immu-
nosuppressants including AZA increases the risk of malignancies, 
particularly non-melanoma skin cancer, and lymphoproliferative dis-
orders.20-22 However, it is unlikely that these long-term risks will be 
influenced by early or delayed initiation of AZA.
The data from our study support both strategies of immediate 
AZA initiation (AASLD) or delayed AZA introduction (EASL), as 
laid out in international guidelines. The main reason to delay AZA 
introduction is to discriminate between AZA-induced hepatotoxic-
ity and non-response to treatment. However, we found that AZA-
induced hepatitis was uncommon and occurred in both groups 
regardless of baseline disease activity, and that AZA-induced hep-
atotoxicity developed only after a median duration of 6 weeks of 
treatment. This suggests that delayed AZA introduction to avoid this 
side effect is not that useful.
In conclusion, the discontinuation rate of AZA in AIH patients is 
~15% in the first year of treatment. Early or delayed AZA initiation 
does not differ in remission and discontinuation rates in AIH induc-
tion therapy. Our data suggest that either strategy may be used as 
part of AIH treatment.
CONFLIC T OF INTERE S T
None declared.
ORCID
Simon Pape  https://orcid.org/0000-0002-3770-4568 
Richard Taubert  https://orcid.org/0000-0001-9270-2496 
Cumali Efe  https://orcid.org/0000-0001-6593-5702 
Heiner Wedemeyer  https://orcid.org/0000-0003-2906-0480 
Ansgar W. Lohse  https://orcid.org/0000-0002-8823-3129 
Joost P. H. Drenth  https://orcid.org/0000-0001-8027-3073 
R E FE R E N C E S
 1. Pape S, Schramm C, Gevers TJ. Clinical management of autoim-
mune hepatitis. United European Gastroenterol J. 2019;7:1156-1163.
 2. Mackay IR, Weiden S, Ungar B. Treatment of active chronic hepa-
titis and lupoid hepatitis with 6-mercaptopurine and azothioprine. 
Lancet. 1964;1:899-902.
 3. Stellon AnthonyJ, Portmann B, Hegarty JohnE, et al. Randomised 
controlled trial of azathioprine withdrawal in autoimmune chronic 
active hepatitis. Lancet. 1985;1:668-670.
 4. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission 
in autoimmune chronic active hepatitis with azathioprine after cor-
ticosteroid withdrawal. Hepatology. 1988;8:781-784.
 5. Lamers MMH, van Oijen MGH, Pronk M, et al. Treatment options 
for autoimmune hepatitis: a systematic review of randomized con-
trolled trials. J Hepatol. 2010;53:191-198.
 6. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term 
maintenance of remission in autoimmune hepatitis. N Engl J Med. 
1995;333:958-963.
 7. Summerskill WH, Korman MG, Ammon HV, et al. Prednisone for 
chronic active liver disease: dose titration, standard dose, and com-
bination with azathioprine compared. Gut. 1975;16:876-883.
 8. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management 
of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.
 9. EASL Clinical Practice Guidelines. Autoimmune hepatitis. J Hepatol. 
2015;63:971-1004.
 10. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the 
diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176.
 11. Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe 
autoimmune hepatitis (AS-AIH): the role of corticosteroids in modi-
fying outcome. J Hepatol. 2014;61:876-882.
 12. Kanzler S, Löhr H, Gerken G, et al. Long-term management and 
prognosis of autoimmune hepatitis (AIH): a single center experi-
ence. Z Gastroenterol. 2001;39(339–41):344-348.
 13. Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol. 
2011;55:171-182.
8  |     PE Et al.
 14. Tragnone A, Bazzocchi G, Aversa G, et al. Acute pancreatitis after 
azathioprine treatment for ulcerative colitis. Ital J Gastroenterol. 
1996;28:102-104.
 15. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia 
related to azathioprine in rheumatoid arthritis. Ann Rheum Dis. 
1988;47:503-505.
 16. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse 
reaction to azathioprine in patients with Crohn's disease compared 
to autoimmune hepatitis: a tertiary referral center experience. Am J 
Gastroenterol. 2005;100:1121-1125.
 17. Dhaliwal HK, Anderson R, Thornhill EL, et al. Clinical significance of 
azathioprine metabolites for the maintenance of remission in auto-
immune hepatitis. Hepatology. 2012;56:1401-1408.
 18. Wusk B, Kullak-Ublick GA, Rammert C, et al. Therapeutic drug 
monitoring of thiopurine drugs in patients with inflammatory 
bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol. 
2004;16:1407-1413.
 19. Rumbo C, Emerick KM, Emre S, et al. Azathioprine metabolite 
measurements in the treatment of autoimmune hepatitis in pe-
diatric patients: a preliminary report. J Pediatr Gastroenterol Nutr. 
2002;35:391-398.
 20. Ngu JH, Gearry RB, Frampton CM, et al. Mortality and the risk of 
malignancy in autoimmune liver diseases: a population-based study 
in Canterbury, New Zealand. Hepatology. 2012;55:522-529.
 21. Aguilar HI, Burgart LJ, Geller A, et al. Azathioprine-induced lym-
phoma manifesting as fulminant hepatic failure. Mayo Clin Proc. 
1997;72:643-645.
 22. van Gerven NMF, Verwer BJ, Witte BI, et al. Epidemiology and 
clinical characteristics of autoimmune hepatitis in the Netherlands. 
Scand J Gastroenterol. 2014;49:1245-1254.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Pape S, Gevers TJG, Vrolijk JM, et al. 
High discontinuation rate of azathioprine in autoimmune 
hepatitis, independent of time of treatment initiation. Liver 
Int. 2020;00:1–8. https://doi.org/10.1111/liv.14513
